Filip E.
- Country
- The Netherlands
- Department
- Department of Neurology
Research Overview
- Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: An Open-label Extension Study
- Phase 2 Multicenter Open-Label Study on Efficacy, Safety, and Tolerability of Riliprubart in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Efficacy and Safety Evaluation of Riliprubart in Refractory Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 3 Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 89 of 186 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on innovative therapeutic approaches for this autoimmune disorder affecting peripheral nerves.
- Standard of care optimization
- Treatment-refractory cases
- Novel therapeutic interventions
Particular emphasis is placed on developing treatment strategies for patients who do not respond to conventional therapies.
Immunological Research
The investigator explores innovative immunomodulatory treatments including new biological agents and subcutaneous formulations for autoimmune conditions.
- Rituximab-based therapies
- Novel antibody treatments
- Long-term remission strategies
Focus includes evaluation of treatments that may reduce dependency on regular immunoglobulin infusions.
Clinical Innovation
Expertise in evaluating advanced therapeutic compounds for neurological conditions, with particular attention to long-term safety and efficacy profiles.
- Subcutaneous drug delivery systems
- Treatment tolerability assessment
- Disease progression monitoring
Research encompasses evaluation of disability scales and long-term patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.